BioMolecular Therapeutics Joins Ranks of RNAi Drug Developers

The company's core technology involves the use of asymmetric siRNAs designed to trigger an RNAi effect while avoiding the immune stimulation associated with traditional siRNAs.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.